Introduction: Breast cancer is the most common malignancy in women in the United States
and triple-negative breast cancer (TNBC) accounts for 15–20%. The standard of care for …

Introduction Triple-negative breast cancer (TNBC) accounts for approximately 10%-15% of
all diagnosed breast cancers and is associated with an aggressive natural history and poor …

Atezolizumab (Tecentriq®), an immune checkpoint inhibitor against programmed death
ligand 1 (PD-L1), is the first immunotherapy agent to be approved (for use in combination …

Background: Triple-negative breast cancer (TNBC) represents an aggressive breast cancer
subtype with historically poor overall outcomes, due primarily to a lack of effective targeted …

Introduction: Triple-negative breast cancer (TNBC) is associated with poor prognosis and
limited treatment options. However, TNBC is known to be more immunogenic compared to …

Background Unresectable locally advanced or metastatic triple-negative (hormone-receptor–
negative and human epidermal growth factor receptor 2 [HER2]–negative) breast cancer is …

Importance Agents targeting programmed death ligand 1 (PD-L1) have demonstrated
efficacy in triple-negative breast cancer (TNBC) when combined with chemotherapy and are …

Immunotherapy has become a mainstay of cancer treatment in many malignancies, though
its application in breast cancer remains limited. Of the breast cancer subtypes, triple …

Background Triple negative breast cancer (TNBC) is clinically aggressive breast cancer with
a poor prognosis. Approximately 20% of TNBC has been found to express programmed …

TPS1104 Background: Treatment for mTNBC is limited, with chemotherapy the mainstay
(bevacizumab is approved in> 80 countries). Atezolizumab (atezo; MPDL3280A), a …